Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by analysts at Citigroup to a "hold" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

REGN has been the topic of several other research reports. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, October 22nd. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a "buy" rating in a report on Tuesday, July 23rd. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Finally, Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

Shares of REGN traded down $25.70 during mid-day trading on Wednesday, reaching $756.81. The company had a trading volume of 1,374,476 shares, compared to its average volume of 530,457. The stock has a market cap of $83.17 billion, a price-to-earnings ratio of 18.93, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15. The firm has a fifty day simple moving average of $992.70 and a 200-day simple moving average of $1,033.92. Regeneron Pharmaceuticals has a fifty-two week low of $753.69 and a fifty-two week high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 7.48% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in REGN. Quent Capital LLC grew its holdings in Regeneron Pharmaceuticals by 5.1% during the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company's stock valued at $375,000 after buying an additional 19 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its position in shares of Regeneron Pharmaceuticals by 26.8% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 587 shares of the biopharmaceutical company's stock valued at $565,000 after acquiring an additional 124 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 37.2% during the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company's stock valued at $59,794,000 after acquiring an additional 16,856 shares during the last quarter. Cercano Management LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $36,953,000. Finally, Edgestream Partners L.P. bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $7,352,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.